Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

NCT00534248 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

22439

Enrollment

INDUSTRY

Sponsor class

Conditions

Shingles

Interventions

BIOLOGICAL: Zoster Vaccine, Live (Zostavax™)
BIOLOGICAL: Comparator: Placebo

Sponsor

Merck Sharp & Dohme LLC